Cancer Immunotherapies and Humanized Mouse Drug Testing Platforms

Page view(s)
Checked on Jan 09, 2023
Cancer Immunotherapies and Humanized Mouse Drug Testing Platforms
Cancer Immunotherapies and Humanized Mouse Drug Testing Platforms
Journal Title:
Translational Oncology
Publication Date:
20 May 2019
Cancer Immunotherapies and Humanized Mouse Drug Testing Platforms1 Author links open overlay panel Qingfeng Chen, Jiaxu Wang, Wai Nam Liu, Yue Zhao
Cancer immunotherapy is a type of treatment that restores and stimulates human immune system to inhibit cancer growth or eradicate cancer. It serves as one of the latest systemic therapies, which has been approved to treat different types of cancer in patients. Nevertheless, the clinical response rate is unsatisfactory and the response observed is mostly a partial response in patients. Despite the continuous improvement and identification of novel cancer immunotherapy, there is a pressing need to establish a robust platform to evaluate the efficacy and safety of pre-clinical drugs, simulate the interaction between patients’ tumor and immune system, and predict patients’ responses to the treatment. In this review, we summarize the pros and cons of existing immuno-oncology assay platforms, especially the humanized mouse models for the screening of cancer immunotherapy drugs. In addition, various emerging trends and progress of utilizing humanized mouse models as the screening tool are discussed. Of note, humanized mouse models can also be used for further development of personalized precision medicines to treat cancer. Collectively, these highlight the significance of humanized mouse models as the important platform for the screening of next generation cancer immunotherapy in vivo.
License type:
Funding Info:
This study was supported by MOH Industry Alignment Fund Cat 2 (MOHIAFCAT 2001), Open fund-large collaborative grant (NMRC/OFLCG/003/2018) and by the Eradication of HBV TCR Program: NMRC/TCR/014- NUHS/2015 and NMRC/TCR/015-NCC/2016 National Medical Research Council Singapore. Qingfeng Chen is also supported by the National Research Foundation Fellowship Singapore NRF-NRFF2017-03.
Files uploaded:

File Size Format Action
1-s20-s193652331930124x-main.pdf 664.11 KB PDF Open